Novo Nordisk Results Q2 2026: Revenue, Profit and Margins

Name: Novo Nordisk quarterly results
Creator: Finpendium
License: https://creativecommons.org/licenses/by/4.0/

Latest report: Novo Nordisk half-year report Jan–Jun 2026, published August 4, 2026

In Q2 2026, Novo Nordisk’s revenue was DKK 78,488.0 million, up 2.1% from Q2 2025. Operating profit was DKK 27,061.0 million, an operating margin of 34.5% (Q2 2025: 43.5%). Net income for the period was DKK 20,989.0 million and earnings per share DKK 4.74.

Novo Nordisk: Where the revenue went, Q2 '26, DKK million. Source: Novo Nordisk half-year report Jan–Jun 2026. — Novo Nordisk: Where the revenue went · Q2 '26, DKK million

Key figures for Q2 2026

Novo Nordisk key figures, Q2 2026 vs Q2 2025
	Q2 2026	Q2 2025	Change
Revenue, DKKM	78,488.0	76,857.0	+2.1%
Gross profit, DKKM	61,388.0	64,011.0	−4.1%
Gross margin	78.2%	83.3%	−5.1 pp
Operating profit, DKKM	27,061.0	33,449.0	−19.1%
Operating margin	34.5%	43.5%	−9.0 pp
Net income, DKKM	20,989.0	26,503.0	−20.8%
Net margin	26.7%	34.5%	−7.7 pp
Earnings per share	DKK 4.74	DKK 5.96	−20.5%

Novo Nordisk in charts

Novo Nordisk: From revenue to net income, Q2 '26, DKK million. Source: Novo Nordisk half-year report Jan–Jun 2026. — Novo Nordisk: From revenue to net income · Q2 '26, DKK million

Novo Nordisk: What drove the change in operating profit, Q2 '25 → Q2 '26, DKK million. Source: Novo Nordisk half-year report Jan–Jun 2026. — Novo Nordisk: What drove the change in operating profit · Q2 '25 → Q2 '26, DKK million

Novo Nordisk: Revenue by segment, Quarterly, DKK million. Source: Novo Nordisk half-year report Jan–Jun 2026. — Novo Nordisk: Revenue by segment · Quarterly, DKK million

Novo Nordisk: Profitability, Quarterly, % of revenue. Source: Novo Nordisk half-year report Jan–Jun 2026. — Novo Nordisk: Profitability · Quarterly, % of revenue

Novo Nordisk: Revenue trend, Quarterly, DKK million. Source: Novo Nordisk half-year report Jan–Jun 2026. — Novo Nordisk: Revenue trend · Quarterly, DKK million

Novo Nordisk: Operating profit trend, Quarterly, DKK million. Source: Novo Nordisk half-year report Jan–Jun 2026. — Novo Nordisk: Operating profit trend · Quarterly, DKK million

Novo Nordisk: Revenue and earnings, last twelve months, Rolling four-quarter sum, DKK million. Source: Novo Nordisk half-year report Jan–Jun 2026. — Novo Nordisk: Revenue and earnings, last twelve months · Rolling four-quarter sum, DKK million

Novo Nordisk: Earnings per share · Quarterly, DKK

Embed this chart

Free to use with the credit link (CC BY 4.0). The embedded chart stays as it is for Q2 2026; this page shows the latest results. Open SVG

Embed code

<figure><a href="https://finpendium.com/companies/novo-nordisk/"><img src="https://finpendium.com/charts/novo-nordisk/2026-q2/eps.svg" alt="Novo Nordisk: Earnings per share, Quarterly, DKK. Source: Novo Nordisk half-year report Jan–Jun 2026." width="800" height="366" style="max-width:100%;height:auto"></a><figcaption>Chart: <a href="https://finpendium.com/companies/novo-nordisk/">Novo Nordisk results on Finpendium</a></figcaption></figure>

Quarterly results

Novo Nordisk quarterly results (DKKM unless stated)
Quarter	Revenue	Change y/y	Operating profit	Operating margin	Net income	EPS
Q2 2026	78,488.0	+2.1%	27,061.0	34.5%	20,989.0	DKK 4.74
Q1 2026	96,823.0	+24.0%	59,618.0	61.6%	48,557.0	DKK 10.93
Q4 2025	79,144.0	−7.6%	31,736.0	40.1%	26,891.0	DKK 6.06
Q3 2025	74,976.0	+5.1%	23,682.0	31.6%	20,006.0	DKK 4.50
Q2 2025	76,857.0	+12.9%	33,449.0	43.5%	26,503.0	DKK 5.96
Q1 2025	78,087.0	+19.5%	38,791.0	49.7%	29,034.0	DKK 6.54
Q4 2024	85,683.0	+30.1%	36,737.0	42.9%	28,230.0	DKK 6.34
Q3 2024	71,311.0	+21.4%	33,822.0	47.4%	27,301.0	DKK 6.13

Annual results

Novo Nordisk annual results (DKKM unless stated)
Year	Revenue	Operating profit	Operating margin	Net income	EPS
2025	309,064.0	127,658.0	41.3%	102,434.0	DKK 23.06
2024	290,403.0	128,339.0	44.2%	100,988.0	DKK 22.67
2023	232,261.0	102,574.0	44.2%	83,683.0	DKK 18.67

Revenue by therapy area

Novo Nordisk revenue by therapy area, Q2 2026 vs Q2 2025 (DKKM)
Therapy area	Q2 2026	Q2 2025	Change
Rare disease	4,907.0	4,919.0	−0.2%
Diabetes and Obesity care	73,581.0	71,938.0	+2.3%

Calculate it yourself

Operating margin calculatorNovo Nordisk in Q2 2026: 34.5%
Net margin calculatorNovo Nordisk in Q2 2026: 26.7%
Gross margin calculatorNovo Nordisk in Q2 2026: 78.2%
Earnings per share calculatorNovo Nordisk in Q2 2026: DKK 4.74

About Novo Nordisk

Novo Nordisk is a Danish pharmaceutical company best known for its diabetes and obesity medicines, such as Ozempic and Wegovy, and also treats rare blood and endocrine diseases.

Sources

Novo Nordisk half-year report Jan–Jun 2026, published Aug 4, 2026
Novo Nordisk interim report Jan–Mar 2026, published May 6, 2026
Novo Nordisk financial statements release 2025, published Feb 3, 2026
Novo Nordisk interim report Jan–Sep 2025, published Nov 5, 2025
Novo Nordisk half-year report Jan–Jun 2025, published Aug 6, 2025
Novo Nordisk interim report Jan–Mar 2025, published May 7, 2025
Novo Nordisk financial statements release 2024, published Feb 5, 2025
Novo Nordisk interim report Jan–Sep 2024, published Nov 6, 2024
Novo Nordisk half-year report Jan–Jun 2024, published Aug 7, 2024

About these figures. All figures come from Novo Nordisk’s published interim reports and financial statements releases, linked above, and are checked against them before publication. Errors are still possible, so confirm any figure in the original report before relying on it. Amounts are in millions of the reporting currency. Quarters reported only cumulatively (for example the fourth quarter) are derived by subtraction, and when a company restates earlier figures, older quarters on the previous basis are left out of comparisons. Margins and changes are calculated by Finpendium. This page is for information only and is not investment advice or a recommendation to buy or sell any security. See how the figures are checked and our Disclaimer. Spotted an error? Let us know.